These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 26719332)

  • 1. Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization.
    Samuel F; Flavin WP; Iqbal S; Pacelli C; Sri Renganathan SD; Trudeau LE; Campbell EM; Fraser PE; Tandon A
    J Biol Chem; 2016 Feb; 291(9):4374-85. PubMed ID: 26719332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production.
    Tapias V; Hu X; Luk KC; Sanders LH; Lee VM; Greenamyre JT
    Cell Mol Life Sci; 2017 Aug; 74(15):2851-2874. PubMed ID: 28534083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease.
    McGlinchey RP; Lacy SM; Huffer KE; Tayebi N; Sidransky E; Lee JC
    J Biol Chem; 2019 Jun; 294(25):9973-9984. PubMed ID: 31092553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.
    Bergeron M; Motter R; Tanaka P; Fauss D; Babcock M; Chiou SS; Nelson S; San Pablo F; Anderson JP
    Neuroscience; 2014 Jan; 256():72-82. PubMed ID: 24128992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes.
    Visanji NP; Wislet-Gendebien S; Oschipok LW; Zhang G; Aubert I; Fraser PE; Tandon A
    J Biol Chem; 2011 Oct; 286(41):35863-35873. PubMed ID: 21849493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.
    Fares MB; Ait-Bouziad N; Dikiy I; Mbefo MK; Jovičić A; Kiely A; Holton JL; Lee SJ; Gitler AD; Eliezer D; Lashuel HA
    Hum Mol Genet; 2014 Sep; 23(17):4491-509. PubMed ID: 24728187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
    Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA
    Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson disease mutant E46K enhances α-synuclein phosphorylation in mammalian cell lines, in yeast, and in vivo.
    Mbefo MK; Fares MB; Paleologou K; Oueslati A; Yin G; Tenreiro S; Pinto M; Outeiro T; Zweckstetter M; Masliah E; Lashuel HA
    J Biol Chem; 2015 Apr; 290(15):9412-27. PubMed ID: 25657004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation of wild-type and mutant alpha-synuclein binding to synaptic membranes by cytosolic factors.
    Wislet-Gendebien S; Visanji NP; Whitehead SN; Marsilio D; Hou W; Figeys D; Fraser PE; Bennett SA; Tandon A
    BMC Neurosci; 2008 Sep; 9():92. PubMed ID: 18808659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective imaging of internalized proteopathic α-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies.
    Karpowicz RJ; Haney CM; Mihaila TS; Sandler RM; Petersson EJ; Lee VM
    J Biol Chem; 2017 Aug; 292(32):13482-13497. PubMed ID: 28611062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation of synucleins by members of the Polo-like kinase family.
    Mbefo MK; Paleologou KE; Boucharaba A; Oueslati A; Schell H; Fournier M; Olschewski D; Yin G; Zweckstetter M; Masliah E; Kahle PJ; Hirling H; Lashuel HA
    J Biol Chem; 2010 Jan; 285(4):2807-22. PubMed ID: 19889641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity.
    Khalaf O; Fauvet B; Oueslati A; Dikiy I; Mahul-Mellier AL; Ruggeri FS; Mbefo MK; Vercruysse F; Dietler G; Lee SJ; Eliezer D; Lashuel HA
    J Biol Chem; 2014 Aug; 289(32):21856-76. PubMed ID: 24936070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
    Braithwaite SP; Stock JB; Mouradian MM
    Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.
    Paleologou KE; Oueslati A; Shakked G; Rospigliosi CC; Kim HY; Lamberto GR; Fernandez CO; Schmid A; Chegini F; Gai WP; Chiappe D; Moniatte M; Schneider BL; Aebischer P; Eliezer D; Zweckstetter M; Masliah E; Lashuel HA
    J Neurosci; 2010 Mar; 30(9):3184-98. PubMed ID: 20203178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
    Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
    PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
    Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
    J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease.
    Wu W; Sung CC; Yu P; Li J; Chung KKK
    PLoS One; 2020; 15(4):e0232019. PubMed ID: 32343709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity.
    Batelli S; Invernizzi RW; Negro A; Calcagno E; Rodilossi S; Forloni G; Albani D
    Neurodegener Dis; 2015; 15(1):13-23. PubMed ID: 25500798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.